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Background: Fibrocystic changes are associated with an increased risk of breast
cancer. Genetic alterations have been found in fibrocystic changes with or without
epithelial changes, suggesting that critical oncogenic events are occurring at an
early stage.
Methods: We investigated a unique collective of 17 breast cancer patients who, prior
to the diagnosis of invasive breast cancer, underwent open surgical biopsy showing
fibrocystic changes of the breast. The time span between biopsy for fibrocystic changes
and invasive carcinoma ranged from 1 to 11 years (average 5.3 years). Ten (58.8%) of the
patients had an ipsilateral invasive carcinoma, and 7 (41.2%) of the patients developed
an invasive carcinoma of the contralateral breast. Massive parallel sequencing targeting
genes frequently mutated in breast cancer was performed on the fibrocystic breast tissue
as well as the ensuing cancer tissue.
Results: In 9 cases, somatic mutations were found in the tumor tissue, the most
prevalent being PIK3CA mutations (n = 4), followed by TP53 mutations (n = 2). None of
these mutations were present in the previously removed mastopathy tissue. In one of the
cases, an ERBB3 E928G mutation was present in the mastopathy as well as in the tumor
tissue, with the variant allele frequency in the mastopathy being <0.1%. In two patients,
we found two mutations (MAP3K1 L380fs and PIK3CA I391M, respectively) present
in the mastopathy as well as in the subsequent breast cancer. These two mutations,
however, could also be due to fixation artifacts.
Conclusion: Since no significant somatic mutations in the fibrocystic breast tissue,
and only doubtful shared mutations between benign and associated cancer tissue
were detected, it remains unclear why women with fibrocystic breast disease have a
statistically significant increased risk of breast cancer. Further analyses, maybe on the
level of gene expression, could help to clarify the role of these benign alterations in the
development of breast cancer and help to identify women at greater risk of developing
subsequent invasive cancer.
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INTRODUCTION
Breast cancer continues to be themost common cancer in women
and represents a major public health issue with 1.38 million new
cases and almost half a million deaths yearly worldwide (1). Since
primary prevention of breast cancer is still not available, efforts to
promote early detection continue to be themajor focus in fighting
this type of tumor, given that early detection is associated with
decreased mortality (2).
Fibrocystic changes of the breast, also called fibrocystic
mastopathy, is a very common benign disease, by which up
to 50% of premenopausal women are affected (3). Fibrocystic
mastopathy encompasses several histopathologic changes such as
cyst formation, apocrine metaplasia, papillomatosis, duct ectasia,
sclerosing adenosis, and stromal fibrosis (4). These changes are
often accompanied by epithelial changes such as usual ductal
hyperplasia (UDH), flat epithelial atypia (FEA), and benign
columnar cell lesions (CCL) (5). Classic fibrocystic changes with
or without epithelial changes are not regarded as a precancerous
lesion, since only a small minority of these women develop
invasive carcinoma. However, women with fibrocystic breast
disease have a significantly increased risk of breast cancer (∼1.5–
2 times that of the general population), which is especially evident
in women 50 years of age and older, and is independent of other
key epidemiologic breast cancer risk (6–8). Although the relative
risk seems low, because of the high frequency of such changes in
the general population, the absolute risk is significant. However,
predicting which patients will progress to invasive cancer remains
difficult, a fact that motivates research aimed at uncovering the
molecular mechanisms at play in these earliest stages of cancer
development (5).
Numerous studies have found genetic aberrations in
histologically normal breast tissue of patients with breast cancer,
indicating a mammary field cancerization (9–11), and the widely
accepted model of breast cancer oncogenesis is that it develops
from benign breast tissue through a succession of genetic
alterations, leading first to in-situ and subsequently to invasive
lesions (12). A recent study using whole-genome sequencing
showed that epithelial changes such as UDH, FEA, and CCL have
already acquired a significant number of genomic alterations,
such as point mutations and chromosome aneuploidies,
suggesting that critical oncogenic events are occurring at this
early stage (13). Many of these alterations are observed in both
the patient’s benign lesions and associated invasive cancer, thus
definitively establishing a genetic relationship. These molecular
alterations are one of the earliest events that affect a large
number of genes and may provide the initial oncogenic potential
and help trigger clonal expansion of imminent breast cancer
cells (13).
In a previous study by our group, FISH analysis revealed that
the estrogen receptor 1- gene (ESR1) was amplified in 15.5%
of breast cancers. Interestingly, women with ESR1 amplification
in breast cancer displayed this amplification even in the benign
fibrocystic breast tissue prior to the first diagnosis of cancer,
and this amplification was absent in fibrocystic tissues from
women who did not develop breast cancer (14). This suggests
that molecular alterations such as ESR1 gene amplifications are
an early event in breast carcinogenesis and are at least in part
already present in fibrocystic breast disease.
The aim of our study was to investigate if patients that
subsequently develop invasive carcinoma of the breast already
exhibit molecular alterations in fibrocystic breast tissue removed
years earlier. For this, we performed targeted massive parallel
sequencing on fibrocystic breast tissue of womenwith subsequent
invasive breast cancer.
MATERIALS AND METHODS
Identification of Patients
We performed an in-depth search of the archive of the Institute
for Pathology formatched specimens from breast cancer patients.
We identified 53 patients with surgically removed invasive breast
cancer. Prior to the breast cancer diagnosis, all patients had
undergone open surgical biopsy where fibrocystic changes of the
breast were diagnosed. None of the patients had an invasive
carcinoma, atypical ductal hyperplasia (ADH) or ductal or
lobular carcinoma in situ (DCIS and LCIS) in these prior biopsies.
For all patients, a normal control sample (lymph node, skin, or
gastric biopsy) was also identified.
The study was conducted in concordance with institutional
patient safety laws and has been approved by the
Ethikkommission Nordwest- und Zentralschweiz (EKNZ,
proposal number 2014-397).
Identification of Appropriate Tissue
H&E slides and formalin-fixed, paraffine-embedded (FFPE)
tissue blocks were retrieved from the archives of the Institute of
Pathology. Where needed, fresh H&E slides were obtained. All
biopsies underwent reevaluation by a certified breast pathologist
(SM) in order to confirm the diagnosis of fibrocystic breast
disease with or without UDH, FEA, or CCL. Cases with atypical
ductal hyperplasia (ADH) or ductal or lobular carcinoma in
situ (DCIS and LCIS) were excluded. Concordantly, all of
the subsequent carcinomas were reevaluated and confirmed.
Subsequently, suitable regions for genomic analyses were
identified on the H&E slides. Since fibrocystic breast disease
consists of glandular structures and cysts as well as a considerable
amount of fatty and/or collagenous tissue, dilution of the
epithelial DNA of interest was minimal. For the invasive breast
cancer, a tumor cell content of >70% was considered sufficient
for DNA analysis. For each patient, normal tissue such as
lymph nodes or gastric biopsies were also sequenced as germline
control. Fresh uncovered H&E slides were cut from the formalin-
fixed and paraffin-embedded tissue. The suitable tissue was
mechanically scraped off, or, in case of few epithelial cells,
removed by laser microdissection to ensure a high purity of the
analyzed cells.
Design of Breast Cancer Gene Panel
A custom targeted sequencing panel focusing on the most
frequently altered genes in breast cancer was designed using Ion
Ampliseq Designer (https://www.ampliseq.com/browse.action;
Thermo Fisher Scientific, MA, USA). The panel covers all exons
of 27 protein-coding genes as well as mutation hotspots in
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three cancer genes are also covered, and the recurrently mutated
lncRNA genes MALAT1 and NEAT1 (Supplementary Table 1)
(15). The panel was designed using the FFPE option for
smaller amplicon size. Notably, our primary interest was
not the screening for novel mutations; instead focused on
a specific panel of already described breast cancer-relevant
mutations and designed amutation panel encompassing themost
relevant genes.
DNA Extraction and Library Preparation
For each of the patients enrolled in this study, genomic DNA
was extracted from the benign fibrocystic breast tissue and
from the tumor biopsies. DNA extracted from a biopsy of
normal tissue, such as lymph nodes or gastric mucosa, served as
germline control. Briefly, representative formalin-fixed paraffin-
embedded histologic blocks were stained with Nuclear Fast
Red in RNase-free condition and subjected to microdissection
with a sterile needle under a stereomicroscope (Olympus) to
ensure a percentage of tumor cells>70%, as described previously
(16). DNA was extracted with the DNeasy Blood and Tissue
Kit (Qiagen, Hilden, Germany) according to manufacturer’s
instructions as previously described (17, 18). DNAwas quantified
using the Qubit Fluorometer (Thermo Fisher Scientific).
Library preparation for the breast panel was performed using
the Ion AmpliSeq library kit 2.0 (Thermo Fisher Scientific)
according to the manufacturer’s guidelines. The panel consists
of two pools of amplification primers. Ten nanogram of DNA
per sample was used for library preparation for each pool.
Amplification was performed according to the manufacturer’s
guidelines. The amplicons from the two pools were combined
and treated to digest the primers and to phosphorylate the
amplicons. The amplicons were then ligated to Ion Adapters
(Thermo Fisher Scientific) using DNA ligase. Finally, cleaning
and purification of the generated libraries were performed with
Agencourt AMPure XP (Beckman Coulter, CA, USA) according
to the manufacturer’s guidelines. Quantification and quality
control were performed with Ion Library TaqMan Quantitation
Kit (Thermo Fisher Scientific). Samples were diluted to reach the
concentration of 40 pmol and then were pooled for sequencing.
Twenty five microliter of the pooled libraries was loaded on
Ion 530 Chip (Thermo Fisher Scientific) and processed in Ion
Chef Instrument (Thermo Fisher Scientific). Sequencing was
performed on Ion S5 XL system (Thermo Fisher Scientific) (18).
Sequence Data Analysis
Sequence reads were aligned to the human reference genome
hg19 using TMAP within the Torrent Suite Software 5.4 for the
Ion S5XL system (17, 18). Somatic mutations were identified
using Torrent Variant Caller v5.0.3 (Thermo Fisher Scientific,
MA, USA). Mutations at hotspot residues were white-listed (19,
20). We filtered out mutations with quality score <60, and/or
supported by <8 reads, and/or those covered by <10 reads in
the tumor or<10 reads in the matched non-tumoral counterpart
(17, 18). Only those for which the tumor variant allele fraction
(VAF) was>10 times that of the matched non-tumoral VAF were
retained to ensure the somatic nature of the variants (17, 18). To
further ensure that the variant calls were not fixation artifacts,
we further classified the variants into confidence tiers based on
(1) whether the mutation affected hotspot residues, (2) VAF and
read depth in both the tumor/mastopathy and germline samples,
(3) whether the variant resulted in C>T/G>A substitution that
is typical of fixation artifacts, (4) whether the variant was a
TABLE 1 | Clinicopathological data of the sequenced breast cancer patients.
Patient Age at cancer
diagnosis
(years)
Localization of
cancer and
mastopathy
Time between mastopathy
biopsy and cancer
diagnosis (years)
Histological
subtype
TNM classification Intrinsic subtype
1 67 Contralateral 5 Invasive ductal pT1c, pN0, G2 Luminal B
2 67 Contralateral 3 Invasive ductal pT1c, pN0; G2 Luminal B
3 39 Ipsilateral 6 Invasive ductal pT2, pN1a, G2 NA
4 46 Contralateral 6 Invasive ductal pT2, pN0, G1 Luminal A
5 49 Contralateral 6 Invasive ductal pT1b, pN0, G3 Luminal A
6 65 Ipsilateral 11 Invasive lobular pT1b, pN1a, G2 Luminal A
7 50 Ipsilateral 5 Invasive ductal pT1c, pN0, G2 Luminal A
8 57 Ipsilateral 7 Invasive ductal pT1c, pN1mi, G2 Luminal A
9 48 Ipsilateral 5 Invasive ductal pT1c, pN0, G3 NA
10 48 Ipsilateral 1 Invasive lobular pT2, pN2, G2 Luminal A
11 61 Ipsilateral 7 Tubulo-lobular pT1c, pN0, G2 Luminal A
12 58 Ipsilateral 3 Invasive ductal pT2, pN2a Luminal A
13 60 Contralateral 5 Invasive ductal pT1a, pN0, G2 Luminal A
14 59 Contralateral 3 Invasive ductal pT2, pN3a, G2 Luminal B, Her2
positive
15 58 Ipsilateral 6 Invasive ductal pT1c, pN0, G2 Luminal A
16 61 Contralateral 7 Invasive ductal pT1b, pN0, G1 Luminal A
17 76 Ipsilateral 4 Invasive ductal pT1, pN0, G1 Luminal A
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homopolymeric insertion/deletion, and (5) whether the variant
was supported by reads from >1 amplicon. Tier 1 mutations
were considered likely genuine mutations, while tier 2 mutations
showed features suggestive of fixation artifact. To account for
somatic mutations that may be present at low VAF in either
the tumor biopsy or the mastopathy but not both, all somatic
mutations identified in one of the two samples were interrogated
for their presence in the matched sample by supplying TVC with
their positions as the “hotspot list” (17). All reported mutations
were manually inspected using the Integrative Genomics Viewer.
RESULTS
Due to fixation artifacts and the age of the tissue samples, we were
only able to perform matched sequencing of mastopathy, control
and cancer tissues on 17 of the 53 identified patients (32%). In the
other cases, the mastopathy or the control tissue was qualitatively
not good enough to be sequenced. For these 17 sequenced
patients, the time span between biopsy for fibrocystic changes
and invasive carcinoma ranged from 1 to 11 years (average 5.3
years, Table 1). Ten (58.8%) of the patients had an ipsilateral
invasive carcinoma, and 7 (41.2%) of the patients developed an
invasive carcinoma of the contralateral breast. Twelve of the
breast cancers (70.5%) were of Luminal A subtype, two (12%)
had a Luminal B subtype, and one of the breast cancers was of
Luminal B, Her2 positive subtype. For two patients, the intrinsic
subtypes were not available. Regarding the histologic subtypes,
the majority (14 of 17 patients, 82%) of the tumors were invasive
ductal carcinomas, with two invasive lobular and one tubule-
lobular subtype, respectively. Twelve patients (70.5%) presented
with stage pT1, and 5 patients (29.5%) presented with stage pT2.
Six of the patients (35%) had lymph node metastases at the
time of surgery. Clinicopathological information can be found
in Table 1.
In 9 cases, somatic mutations were found in the tumor tissue,
including hotspot mutations in PIK3CA (n = 4) and TP53 (n
= 2, Table 1). None of these hotspot mutations were present
in the previously removed mastopathy tissue, despite achieving
an average sequencing depth of 2516x (range 814x−5654x).
We further identified an additional 15 mutations in PIK3CA,
TABLE 2 | Somatic mutations detected in mastopathy and subsequent breast cancer.
Patient Mutations tier 1 confidence Mutations tier 2 confidence
1 Tumor: MAP3K1 L380 PRESENT, MAP3K1 P1474fs PRESENT, PIK3CA stop
lost PRESENT
Mastopathy: MAP3K1 L380 PRESENT, MAP3K1 P1474fs ABSENT, PIK3CA
stop lost ABSENT
2 Tumor: GATA3 A333fs PRESENT
Mastopathy: GATA3 A333fs ABSENT
Tumor: FBXW7c.1122+1G>A PRESENT
Mastopathy: FBXW7c.1122+1G>A ABSENT
3
4
5
6 Tumor: ERBB3 E928G PRESENT, PIK3CA stop lost PRESENT
Mastopathy: ERBB3 E928G PRESENT (<0.1% VAF), PIK3CA stop
lost ABSENT
7 Tumor: TP53 I195T PRESENT
Mastopathy: TP53 I195T ABSENT
8 Tumor: KMT2C (MLL3) c.590+1G>C PRESENT
Mastopathy: KMT2C (MLL3) c.590+1G>C ABSENT
9 Tumor: GATA3 S428fs PRESENT
Mastopathy: GATA3 S428fs ABSENT
10 Tumor: PIK3CA C378Y PRESENT
Mastopathy: PIK3CA C378Y ABSENT
11 Tumor: ARID1A G444S PRESENT
Mastopathy: ARID1A G444S ABSENT
12 Tumor: PIK3CA H1047R PRESENT
Mastopathy: PIK3CA H1047R ABSENT
Tumor: PIK3CA I391M present
Mastopathy: PIK3CA I391M present
13
14 Tumor: PIK3CA E545G, TP53 R248W, PIK3C1 K567_L570del PRESENT
Mastopathy: PIK3CA E545G, TP53 R248W, PIK3C1
K567_L570del ABSENT
15 Tumor: KMT2C (MLL3) C1004F PRESENT
Mastopathy: KMT2C (MLL3) C1004F ABSENT
16 Tumor: PIK3CA H1047R PRESENT, MAP3K1 L838fs PRESENT
Mastopathy: PIK3CA H1047R ABSENT, MAP3K1 L838fs ABSENT
Tumor: MAP3K1 R273fs PRESENT
Mastopathy: MAP3K1 R273fs ABSENT
17 Tumor: GATA3 D336fs PRESENT
Mastopathy: GATA3 D336fs ABSENT
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MAP3K1, GATA3, ERBB3, ARID1A, PIK3R1, and KMT2C, most
of which were not detected in the corresponding mastopathies.
In one of the cases, an ERBB3 E928G mutation was present
in the mastopathy as well as in the tumor tissue, although the
variant allele frequency in the mastopathy was <0.1%. In one
case, a MAP3K1 L380fs mutation was present in the mastopathy
as well as in the tumor tissue, and in another case, a PIK3CA
I391M mutation was present in the mastopathy as well as in
the subsequent breast cancer. These last two mutations, however,
could also be due to fixation artifacts. The detected mutations
for each patient can be found in Table 2. Sequencing data are
available at the European Genome-phenome Archive under the
accession EGAS00001003563.
DISCUSSION
This is one of the first studies using a targeted breast cancer
gene panel and massive parallel sequencing on fibrocystic breast
tissues that were diagnosed years before the development of
subsequent invasive breast cancer in order to understand the
genomic landscape of these benign breast tissue changes. By
investigating a unique collective of 53 breast cancer patients,
of whom benign pre-cancerous tissue was available for genetic
analysis, we hoped to identify early molecular alterations
important for breast cancer carcinogenesis. Unfortunately, due
to fixation artifacts and inferior DNA quality, we were only able
to successfully sequence mastopathy tissue, tumor tissue and
control tissue from a total of 17 patients, which is certainly the
greatest limitation of our study.
None of these 17 patients had any significant mutations in
the mastopathy tissue, challenging the notion that early genetic
alterations are regularly present in benign breast tissue prior
to the development of breast cancer. Whether this absence of
any mutations in the mastopathy tissue is due to a lack of
genetic alteration or due to sample size limitation or impaired
DNA quality, we cannot say with confidence. We detected three
putative mutations in the mastopathies, but these mutations
were either low VAF or were possibly fixation artifacts. On
the other hand, in the five cases in which hotspot TP53 or
PIK3CAmutations were detected in the tumor, none of them was
detected in the mastopathy despite an average depth of 2516x in
the samples.
PIK3CA and TP53 constitute two driver genes that are
recurrently altered at high frequency (up to 30%) in invasive
breast cancers (21). Moreover, PIK3CAmutations are enriched in
ER + tumors (up to 45%), which corresponds to the ER+ status
of all five tumors with identified hotspot mutations in our study.
The mutations identified in the tumor tissue thus fit nicely into
the known mutational landscape of breast cancer.
In light of our results we have to assume that benign breast
tissue with fibrocystic changes does not routinely harbor any
oncogenic mutations, in contrast to premalignant lesions such as
ADH, DCIS, and LCIS.
A recent study by Rohan et al. also investigated the occurrence
of somatic mutations in benign breast tissue of 218 patients who
later developed invasive breast cancer (22). While identifying
a total of 504 somatic mutations in the benign breast tissue,
they found no significant difference in the overall mutation
burden when compared to patients who did not develop cancer.
Importantly however, the authors included proliferative lesions
with atypia (ADH, ALH) into their benign breast lesions, which
could account for the high number of somatic mutations detected
in their collective. ADH and ALH both have 3- to 5-fold
higher risk for subsequent invasive breast cancer compared
to women with non-proliferative breast lesions (23) and are
known to harbor genetic alterations (24, 25). Moreover, ADH
is also considered to be a direct but non-obligate precursor to
carcinoma (26).
Rohan et al. also compared the benign breast biopsies with
tissue samples from the subsequent ipsilateral invasive breast
cancer in 7 patients, and, in accordance with the results of our
study, were not able to identify any sharedmutations between the
benign and the cancer tissue (22). One explanation for this is that
since the sequenced mastopathy tissue was removed years earlier
in our patients, it did not give rise to the subsequent invasive
cancer. The cancer most probably developed through precursor
lesion in adjacent breast tissue, or, in case of contralateral invasive
carcinomas, in the tissue of the contralateral breast, which was
not initially sampled.
Taking into consideration the negative results of our study, it
thus remains unclear why women with fibrocystic breast disease
have a statistically significant increased risk of breast cancer.
Further analyses of these fibrocystic changes, perhaps on the level
of gene expression, could help to clarify the role that these benign
alterations play in the development of breast cancer and help
to identify women with greater risk of developing subsequent
invasive cancer.
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